MetLife Investment Management’s Apogee Therapeutics APGE Stock Holding History

MetLife Investment Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Buy	24,247 +2,936	+14%	+$213K	0.01%	1048
2025 Q4	$1.61M	Buy	21,311 +2,073	+11%	+$131K	0.01%	1184
2025 Q3	$764K	Hold	19,238	–	–	﹤0.01%	1603
2025 Q2	$836K	Sell	19,238 -3,367	-15%	-$128K	﹤0.01%	1403
2025 Q1	$845K	Sell	22,605 -355	-2%	-$13.7K	﹤0.01%	1446
2024 Q4	$1.04M	Buy	22,960 +1,845	+9%	+$94.1K	0.01%	1387
2024 Q3	$1.24M	Buy	21,115 +80	+0.4%	+$3.83K	0.01%	1266
2024 Q2	$828K	Sell	21,035 -194	-0.9%	-$9.42K	﹤0.01%	1444
2024 Q1	$1.41M	Buy	21,229 +10,591	+100%	+$462K	0.01%	1115
2023 Q4	$297K	Hold	10,638	–	–	﹤0.01%	2009
2023 Q3	$227K	Buy	+10,638	New	+$234K	﹤0.01%	2134

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

MetLife Investment Management's APGE Position: Q1 2026 in Review

MetLife Investment Management increased its Apogee Therapeutics (APGE) stake by 14% in Q1 2026, buying an estimated $213K and bringing the position to 24,247 shares worth $2.04M. The position accounts for 0.01% of the portfolio, ranked #1048.

MetLife Investment Management first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

MetLife Investment Management held 24,247 shares of Apogee Therapeutics worth $2.04M as of Q1 2026.
MetLife Investment Management bought 2,936 Apogee Therapeutics shares in Q1 2026, an estimated $213K.
Apogee Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1048 holding.
MetLife Investment Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.